Aptahem’s business strategy is to perform proactive development activities targeted towards future partners by frequently interacting and discussing with pharmaceutical and biotech companies that have commercial synergies with the company’s technology. The aim of these activities is to establish successful partnerships or license agreements that could generate resources for promoting the company’s portfolio of drug candidates and strengthen the company’s value. The company’s objective is to sign such an agreement linked to the Apta-1 drug candidate at an early stage of clinical development.
The company implements a cost-effective competence strategy by recruiting and project-managing consultants with documented expertise in their fields within business management, pharmaceutical development, clinical trials, regulatory procedure, licensing and patent applications. This strategy ensures good flexibility in relation to continuously changing requirements for specialist knowledge in the development of the company’s drug candidates. The company is furthermore implementing a proactive strategy in intellectual property in order to safeguard continual growth of the company’s portfolio value and promote the company’s position in future negotiations with partners.